


Express Mail Label No.

Dated: \_\_\_\_\_

Docket No.: 04287/100M315-US1  
(PATENT)



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Arthur Ramazanov et al.

Application No.: 10/660,256

Confirmation No.: 5361

Filed: September 11, 2003

Art Unit: 1614

For: A NOVEL COMPOSITION FOR THE  
TREATMENT OF OBESITY AND  
EFFECTIVE FAT LOSS PROMOTION

Examiner: P. G. Spivack

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. 1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 C.F.R. 1.97, as it is filed:

(Check one of the boxes A-D)

- A. Within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.
- B. before the mailing date of a first office action on the merits, or a first office action after filing a request for continued examination.
- C. after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary statement in box "i" below or paid the necessary fee in box "ii" below.

(check one of the boxes "i" and "ii" below:)

- [ ] i. Counsel states that, upon information and belief, each item of information listed herein was either (a) first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.
- [X] ii. A check for the fee set forth in 1. 17(p), presently believed to be \$180, is enclosed.
- [ ] D. after (A), (B) and (C) above, but before payment of the issue fee: Applicant petitions under 37 C.F.R. 1.97(d) for the consideration of this IDS. Under 37 CFR 1.17(i) a check in the amount of \$180.00 is enclosed. Counsel certifies that, upon information and belief, each item of information listed herein was either (i) cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the IDS; or (ii) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.

2. In accordance with 37 C.F.R. 1.98, this IDS includes a list (e.g., form PTO/SB/08) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.

(check boxes A, B and/or C and fill in blanks, if appropriate.)

- [ ] A. Pursuant to the Notice issued by the United States Patent and Trademark Office dated July 11, 2003 waiving the requirements of 37 C.F.R. § 1.98(a)(2)(i), a copy/copies of the United States Patent on PTO/SB08 is/are not being submitted.
- [ ] B. Document(s) \_\_\_\_\_ is (are) deemed substantially cumulative to document(s) \_\_\_\_\_, and, in accordance with 1.98(c), only a copy of each of the latter documents is enclosed.
- [ ] C. Certain documents were previously cited by or submitted to the Office in the following prior applications, which are relied upon under 35 U.S.C. 120:

[SERIAL NO. & FILING DATE].

Applicant identifies these documents by attaching hereto copies of the forms PTO-892, PTO-1449 and/or PTO/SB/08 from the files of the prior application(s) or a fresh PTO/SB/08 listing these

documents, and request that they be considered and made of record in accordance with 1.98(d). Per 37 CFR 1.98(d), copies of these documents need not be filed in this application.

3. Cite Nos. \_\_\_\_ and \_\_\_\_ are not in the English language. In accordance with 1.98(c),

Applicant states:

- An English translation of each document (or of the pertinent portions thereof), or a copy of each corresponding English-language patent or application, or English-language abstract (or claim) is enclosed.
- The requirement for a concise explanation of the relevance of any foreign language document is satisfied by the attached search report; citation of the documents cited in the search report shall not be construed as an admission that they are or are considered to be, material to patentability of the subject matter claimed herein (See MPEP §609).
- A concise explanation of the relevance of document(s) \_\_\_\_\_ is set forth as follows: [Insert concise explanation of relevance]
- A concise explanation of the relevance of document(s) \_\_\_\_\_ can be found on page(s) \_\_\_\_\_ of the specification.
- A concise explanation of document(s) \_\_\_\_\_ can be found on the attached sheet.

4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 in the preamble to the final rules; 1135 OG 13 at 20).

5. Other information being provided for the examiner's consideration follows:

6. In accordance with 37 C.F.R. 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless other-wise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

**CROSS REFERENCE UNDER 37 C.F.R. (1.78 TO RELATED APPLICATIONS**


Pursuant to 37 C.F.R. ( 1.78, Applicant notes that the above-identified patent application may be related to the following U.S. Patent Applications:

(1) U.S. Patent Application Serial No \_\_\_\_\_, filed \_\_\_\_\_.

Early and favorable consideration is earnestly solicited.


Dated: March 17, 2006

Respectfully submitted,

By 

Stephanie R. Amoroso

Registration No.: 51,401  
DARBY & DARBY P.C.  
P.O. Box 5257  
New York, New York 10150-5257  
(212) 527-7700  
(212) 527-7701 (Fax)  
Attorneys/Agents For Applicant



the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/660,256-Conf. #5361
				Filing Date	September 11, 2003
				First Named Inventor	Arthur Ramazanov
				Art Unit	1614
				Examiner Name	P. G. Spivack
Sheet	1	of	3	Attorney Docket Number	04287/100M315-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AA*	US-6,827,950-A1		02-19-2004	Hong et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
BA	JP-2002-187845		07-05-2002		✓

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			

1	Aleshkina, Y. A. (1962). Pharmacological Properties of <i>Aralia Mandshurica</i> Institute of Medicinal Plants, Russian Academy of Science. Medicinal Plants of Russia, Moscow, Russia pp. 258-264.	
2	Arimura N, et al. (2004). The peroxisome proliferator-activated receptor gamma regulates expression of the perilipin gene in adipocytes. <i>Biol Chem.</i> 12; 279(11):10070-10076.	
3	Brasaemle DL, et al. (2004). Proteomic Analysis of Proteins Associated with Lipid Droplets of Basal and Lipolytically Stimulated 3T3-L1 Adipocytes* <i>J. Biol. Chem.</i> , Vol. 279, Issue 45, 46835-46842	
4	Chen TH, et al., (2001). The in vitro inhibitory effect of flavonoid astilbin on 3-hydroxy-3-methylglutaryl coenzyme A reductase on Vero cells. <i>Zhonghua Yi Xue Za Zhi (Taipei)</i> . 64(7):382-387.	
5	Chung CK, Jung ME. (2003). Ethanol fraction of <i>Aralia elata</i> Seemann enhances antioxidant activity and lowers serum lipids in rats when administered with benzo(a)pyrene. <i>Biol Pharm Bull.</i> 26(10): 1502-1504	
6	Dzhumaeva TI, Radivoz MI, Kondakova EN. (1980). Androgenic effect of <i>Aralia mandshurica</i> extract. <i>Pharmacy in Russian Far East</i> , p. 92-95.	
7	Dyakov DI. (1971). On the Influence of <i>Aralia mandshurica</i> on the Pulse Arterial Pressure during Prescribed Physical Workloads". Biologically Active Substances from Flora and Fauna of the Far East and Pacific Ocean. Vladivostok, 117-118.	
8	Garcia A., et al. (2004) The amino and carboxyl termini of perilipin a facilitate the storage of triacylglycerols. <i>J Biol Chem.</i> 279(9):8409-8416.	
9	Gubchenko PP, Fruentov NK (1982). A comparative study of effectiveness of adaptogenic plants <i>Aralia mandshurica</i> , <i>Eleutherococcus</i> and other plants adaptogens as agents for enhancing the working capacity of the flying personnel. Khabarovsk State Medical Institute, Khabarovsk, USSR.	
10	Gubina G.P. (1962). Clinical Applications of <i>Aralia mandshurica</i> Tincture. In <i>Medicinal Phytopreparations from plants</i> , Moscow, Russia 263-269.	

Examiner Signature	Date Considered
--------------------	-----------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet	2	of	3	Application Number	10/660,256-Conf. #5361
				Filing Date	September 11, 2003
				First Named Inventor	Arthur Ramazanov
				Art Unit	1614
				Examiner Name	P. G. Spivack
				Attorney Docket Number	04287/100M315-US1

11	Ivanov IS, Savkina GD, S.Ya. Sokolov Sya (1971). Treatment of Periodontitis with Saparal. Central Scientific Research Institute of Stomatology, Moscow. In: Biologically active substances in the flora and fauna of the Soviet Far East and Pacific Ocean. Vladivostok; Russia, 1971, pp. 122-123.	
12	Kazakevich VV (1971). The Effect of <i>Aralia Mandshurica</i> extract on Physical Work Capacity of Animals and Humans. Medical Institute, Khabarovsk. In: Biologically active compounds in flora and fauna of Soviet Far East. pp. 119-120	
13	Kazakevich VV. (1972). On the Influence of <i>Aralia mandshurica</i> tincture on the Central Nervous System: In Medicinal Remedies of the Far East. Vladivostok: Far East Scientific Center of the Academy of Science of the USSR, 186-189.	
14	Kern PA, et al. (2004). Perilipin Expression in Human Adipose Tissue Is Elevated with Obesity The Journal of Clinical Endocrinology & Metabolism Vol. 89, No. 3 1352-1358	
15	Kim JS, Shim SH, Chae S, Han SJ, Kang SS, Son KH, Chang HW, Kim HP, Bae K (2005) Saponins and other constituents from the leaves of <i>Aralia elata</i> . Chem Pharm Bull (Tokyo). 53(6): 696-700.	
16	Komissarenko BT (1962). Aralia - A New Stimulating and Tonic Agent. <u>Soviet Medicine (Sovetskaya meditsina)</u> ; 95, No.3; pp 115-117.	
17	Kryukovskaya, E.V., Kudrin A.N (1991). Effect of <i>Aralia mandshurica</i> extract on Adaptive mechanisms and Tolerance of Central Nervous system under Ischemic condition. I.M. Sechenov First Moscow Medical Institute. Pharmacology and Toxicology, pp. 47-50.	
18	Lee EB, Kim OJ, Kang SS, Jeong C. (2005) Araloside A, an anti-ulcer constituent from the root bark of <i>Aralia elata</i> . Biol Pharm Bull. 28(3): 523-6	
19	Levin RM, Leggett RE, Whitbeck C, Murakami T, Kambara T, Aikawa K (2004) Oral Kohki Tea and its protective effect against in vitro ischemic damage to the bladder. Neurourol Urodyn. 23 (4): 355-360.	
20	Levin RM, Kawashima Y, Leggett RE, Whitbeck C, Horan P, Mizutani K. (2002) Effect of oral Kohki tea on bladder dysfunction induced by severe partial outlet obstruction. J Urol. 167(5): 2260-2266.	
21	Levin RM, Leggett RE, Whitbeck C, Matsumoto S., Ohto N., Ikeda T., Mizutani K (2006) Kohki Tea protects rabbit bladder from Ischemia/Reperfusion-Induced Contractile dysfunction. Neurourol Urodyn. In Press.	
22	Plotnikov MB, Plotnikov DM, et al. (2004). Hemorheological and antioxidant effects of Ascovertin in patients with sclerosis of cerebral arteries. Clin Hemorheol Microcirc. 30(3-4): 449-52.	
23	Russian Pharmacopoeia, 1982. USSR MINISTRY OF HEALTH ADMINISTRATION FOR INTRODUCTION OF NEW THERAPEUTIC AGENTS AND MEDICAL TECHNOLOGY PHARMACOPOEIA COMMITTEE. Moscow-1982	
24	Sim Joon-Soo, Hai Lin Zhao, Da Wei Li, et al. (2005) Effects of Saponins from the Root Bark of <i>Aralia elata</i> on the Transport of Chondroitin Sulfate in Caco-2 Cell Monolayers and Rats Biol. Pharm. Bull. 28(6) 1043-1048	
25	Sokolov SYa, Monogarov VD, Sobolev VL, et al. (1971). The Effect of <i>Aralia Mandshurica</i> Saponins On Recovery Processes in Sportsmen Following Heavy Physical Loads. "Biologically active substances in the flora and fauna of the Soviet Far East and Pacific Ocean." Vladivostok; 1971, pp. 113-114.	
26	Sokolov SYa (1971). The Dependence Between Chemical Structure and Neurotropic Action of Glycosides of Oleonolic Acid. In: Biologically active substances in the flora and fauna of the Soviet Far East and Pacific Ocean. Vladivostok; 1971, pp. 40-41.	
27	Sokolov S.Ya, Ostrovsky NN, Maksimova RG, et al. (1971). Experimental Pharmacological and Clinical Study of the Tonicizing Properties Of Aralosides from <i>Aralia Mandshurica</i> . All-Union Institute of Medicinal Plants, Moscow. Biologically active substances in the flora and fauna of the Soviet Far East and Pacific Ocean. Vladivostok; 1971, pp. 41-42.	

Examiner Signature	Date Considered	
--------------------	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete If Known</b>	
Sheet	3	of	3	Application Number	10/660,256-Conf. #5361
				Filing Date	September 11, 2003
				First Named Inventor	Arthur Ramazanov
				Art Unit	1614
				Examiner Name	P. G. Spivack
				Attorney Docket Number	04287/100M315-US1

28	Sokolov S Ya. (1982). Pharmacological Properties of Aralia Mandshurica Saponins. Russian Academy of Science. In: <i>Medicinal Agents from Plants</i> ; Editor: Prof. A.D. Turova. Moscow, State Publishing Press for Medicinal Sciences, pp 270-277.	
29	Tomatsu M, Ohnishi-Kameyama M, Shibamoto N. (2003). Aralin, a new cytotoxic protein from <i>Aralia elata</i> , inducing apoptosis in human cancer cells. <i>Cancer Lett.</i> 199 (1): 19-25.	
30	Turova AD (1974). <i>Aralia mandshurica</i> (Thorn tree) Rupr. At Maxim. In: <i>Medicinal Plants of USSR and their application</i> . Moscow, Medicine Press. Ed. AD Turova, pp. 21-26.	
31	Yamahara J (2002). Method of producing anti-obesity drug from buds of a plant <i>Aralia elata</i> . Japanese Patent JP2002187845, Published 2002-07-05.	
32	Yan R, Xu Q (2001) Astilbin selectively facilitates the apoptosis of interleukin-2-dependent phytohemagglutinin-activated Jurkat cells. <i>Pharmacol Res.</i> 44 (2):135-139.	
33	Yatsino AI, Seyfulla Khl, Turova AD (1971) Neurotropic Properties of Tinctures of <i>Aralia Mandshurica</i> and Schmidt's <i>Aralia</i> In a Comparative Study. Biologically active substances in the flora and fauna of the Soviet Far East and Pacific Ocean. Vladivostok; pp. 42-44.	
34	Yoshikawa M., Yamahara J (1996). Inhibitory effect of oleanene-type triterpene oligoglycosides on ethanol absorption: the structure -activity relationships. IN: <i>Saponins Used in Traditional and Modern Medicine</i> . Ed. By Walter & Yamasaki. Plenum Press, New York, pp. 207-217.	
35	Xu Q, Wu F, Cao J, Chen T, Jiang J, Saiki I, Koda A. (1999). Astilbin selectively induces dysfunction of liver-infiltrating cells--novel protection from liver damage. <i>Eur J Pharmacol.</i> 377(1):93-100.	
36	Wang Y., et al. (2003). Perilipin Expression in Human Adipose Tissues: Effects of Severe Obesity, Gender, and Depot. <i>Obes Res.</i> 11(8):930-936.	
37	Zhang HH., et al. (2003). Lipase-selective Functional Domains of Perilipin A Differentially Regulate Constitutive and Protein Kinase A-stimulated Lipolysis. <i>J. Biol. Chem.</i> , Vol. 278, Issue 51, 51535-51542.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------